Tortosa

Researchers are evaluating the effects of energy supplementation with carbohydrate-rich sports gels compared to a low-sugar sports drink during labor in low-risk pregnant women receiving epidural analgesia. The study aims to understand if carbohydrate solutions can improve maternal and neonatal outcomes such as labor duration and other obstetric factors. This pilot randomized, triple-blind clinical trial will provide preliminary data to inform a larger future trial. Participants will be randomly assigned to receive either a high-carbohydrate sports gel or a low-carbohydrate hydrogel that matches the gel in appearance and texture. The first dose is given 60 minutes after epidural analgesia, followed by repeated doses every 3 hours during active labor, with up to four doses total. Water intake is encouraged throughout labor. Both interventions are administered as oral supplements to support energy needs during labor. During the study, participants will be monitored from epidural placement until delivery and postpartum. Researchers will assess labor duration, blood glucose levels in mothers and newborns, cardiotocography patterns, maternal vomiting, postpartum hemorrhage, neonatal Apgar scores, and maternal satisfaction. The study includes continuous observation and collection of clinical data to evaluate safety and effectiveness of the nutritional supplementation over the course of labor and shortly after birth.

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are evaluating a continuity of care intervention aimed at improving metabolic control in adults with type 2 diabetes mellitus T2DM in the Terres de lEbre health region. This randomized, parallel-group clinical trial is led by the Endocrinology Service at Hospital de Tortosa Verge de la Cinta and focuses on training primary care professionals through structured, multidisciplinary education and feedback. The study addresses challenges in managing T2DM including glycemic control and cardiovascular risk, with HbA1c as the primary marker. The intervention involves onsite training sessions delivered by endocrinologists and nurse educators to primary care physicians and nurses at selected centers. Training consists of six modules combining theoretical and practical content related to diabetes management, cardiovascular risk reduction, and diabetic foot care. These sessions occur biweekly over one year from July 2025 to July 2026, with each participating center receiving 15 sessions. Centers are randomized to either receive this training or continue usual care without the specific continuity-of-care training. Participants with T2DM will be assessed at baseline, 6, 12, and 24 months for HbA1c and secondary health outcomes like cholesterol levels, blood pressure, BMI, and adherence to screening protocols. The study also collects professional feedback through focus groups before and after the intervention to understand barriers and facilitators. Data are anonymized, and the study aims to provide evidence on the effectiveness of multidisciplinary care continuity in a primary care setting over a two-year follow-up period.

This observational study focuses on pregnant women in their third trimester, aiming to understand how physical fitness and emotional well-being can help predict the type of birth they will have, such as natural vaginal birth, cesarean section, or medically assisted birth. The study also explores whether a womans physical activity and confidence during pregnancy influence her ability to breastfeed successfully for up to six months. Participants will perform two simple physical tests during a clinic visit a hand-grip strength test and a 30-second chair stand test. They will also complete surveys about their daily physical activity, feelings and fears related to childbirth, and confidence in managing the final stages of birth and pushing. Follow-up phone calls will be conducted one month and six months after birth to discuss breastfeeding progress. Throughout the study, researchers will measure the mode of birth at delivery and breastfeeding maintenance at one and six months postpartum. Participants will be asked about their physical activity and emotional state during pregnancy, and their breastfeeding experience after birth. The study is expected to run from June 2026 to December 2027, with primary data collection completing by June 2027.

Researchers are investigating the long-term recovery of adults who survived acute respiratory distress syndrome ARDS, comparing those whose ARDS was caused by COVID-19 with those who had ARDS from other causes. The study aims to identify risk factors for lasting lung problems, including lung diffusing capacity, and to understand recovery across multiple areas such as symptoms, quality of life, cognitive function, lung function, exercise capacity, chest imaging, and molecular profiles. This observational study seeks to improve understanding of severe lung injury and support personalized care for survivors. Adult survivors of ARDS, whether caused by severe pneumonia or other origins, will be followed for one year after hospital discharge. Evaluations occur at 3, 6, and 12 months and include symptom assessments, neurocognitive tests, lung function tests, exercise tests, chest CT scans, and molecular analyses. Patients are grouped based on whether they had ARDS or severe pneumonia without ARDS. Data from COVID-19 ARDS survivors will also be used for comparison. Participants will undergo comprehensive evaluations at each follow-up visit, including questionnaires on symptoms, quality of life, cognitive and memory assessments, lung function tests, exercise capacity tests, and chest imaging. Researchers will analyze changes in lung diffusing capacity, lung volumes, and chest CT findings over time. Additional outcomes include cognitive status, fatigue, anxiety, independence in daily activities, and molecular profile identification. The study will also develop clinical tools to predict lung problems and design cost-effective follow-up plans for ARDS survivors.

Researchers are evaluating treatments for community-acquired pneumonia CAP, especially in patients admitted to intensive care units ICUs. This trial also adapts to study treatments for respiratory pandemics like COVID-19. The goal is to determine which treatment strategies improve outcomes for patients with severe pneumonia, using a flexible, ongoing approach that can test multiple therapies simultaneously and update as new information becomes available. Participants receive different treatment strategies based on random assignment to study groups. Treatments include various antibiotics, steroids, antivirals, immune modulators, anticoagulation methods, and ventilation strategies. Some treatment options have been closed to recruitment, reflecting the trials adaptive nature. The trial includes several domains targeting specific infections such as influenza and COVID-19, with dosing and duration guided by clinical practice and local guidelines. During the study, participants are monitored closely with assessments including survival up to 90 days, days alive without organ support in ICU, ICU and hospital length of stay, ventilator-free days, organ failure-free days, and quality of life up to 6 months. Researchers collect detailed data on patient outcomes, organ support needs, and hospital discharge status. The study runs until February 2028, with ongoing evaluation to improve pneumonia treatment strategies in ICU settings and during respiratory pandemics.

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.

Researchers are studying adults aged 18 to 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia Ph-negative ALL. The study evaluates treatment outcomes based on measurable residual disease MRD status and genetic testing done at the start. The goal is to tailor therapy after initial consolidation to improve survival and remission rates. Patients initially receive a four-drug induction chemotherapy regimen including vincristine, prednisone, pegylated asparaginase, and daunorubicin. Those who do not respond may receive a second induction with fludarabine, cytarabine, G-CSF, and idarubicin. Patients with good MRD clearance and favorable genetics continue with early and delayed consolidation, reinduction, and maintenance chemotherapy using pediatric-type protocols. Others may proceed to allogeneic hematopoietic stem cell transplantation alloHSCT. Participants will undergo regular assessments of MRD after induction and consolidation phases, along with monitoring for complete remission at 4 to 8 weeks. Researchers will track overall survival for 3 years. Safety and treatment responses are evaluated throughout, with ongoing follow-up. The total study duration includes treatment periods and observation to assess long-term outcomes under the guidance of the PETHEMA Foundation.